Challenges of Blood Centres in Providing Compatible Packed Red Blood Cells in Thalassemia Patients

Sangeeta Pathak¹*

¹ Department of Transfusion Services, Max Super Speciality Hospital, Saket, New Delhi

Abstract:

Thalassemia is a hereditary haemoglobinopathy characterised by ineffective erythropoiesis and chronic anaemia, necessitating lifelong regular packed red blood cell (PRBC) transfusions. While transfusion therapy remains the cornerstone of management and significantly improves survival and quality of life, it presents complex challenges for both patients and blood centres. Repeated transfusions expose patients to risks such as alloimmunisation, autoantibody formation, transfusional iron overload, and transfusion-transmitted infections (TTIs), all of which complicate long-term care and transfusion support. Alloimmunisation, in particular, poses a major obstacle by limiting the availability of compatible PRBC units and increasing the risk of haemolytic transfusion reactions. From the blood centre perspective, ensuring the timely provision of antigen-matched, compatible blood for multi-transfused thalassemia patients is demanding due to limited donor phenotyping, scarcity of rare blood groups, and the need for advanced immunohaematology testing. The implementation of extended antigen matching, molecular genotyping, maintenance of rare donor registries, and regular antibody screening are critical strategies to mitigate transfusion-related complications. However, these measures require significant infrastructure, expertise, and financial investment, which may be challenging in resource-constrained settings. This article highlights the multifaceted challenges faced by blood centres in providing compatible PRBCs to thalassemia patients and emphasises the importance of a proactive, multidisciplinary transfusion strategy. Strengthening donor programmes, adopting advanced testing technologies, and fostering collaboration among transfusion services are essential to improving transfusion safety and outcomes in transfusion-dependent thalassemia.

Key words: Thalassemia, Alloimmunisation, Iron Overload, Chronic Anaemia, Transfusion-Transmitted Infections, Red Blood Cell Transfusions.

Introduction

Thalassemia is a genetic blood disorder characterised by defective haemoglobin production, leading to chronic anaemia and necessitating lifelong red blood cell (RBC) transfusions. While transfusions significantly enhance the quality of life for patients, they also present numerous challenges, both for the patients and for blood bankers who are responsible for ensuring safe and effective transfusion therapy. These challenges range from alloimmunisation and iron overload to the availability of compatible donor units and the risks of transfusiontransmitted infections. ¹ Addressing these challenges requires a comprehensive, multidisciplinary approach to optimise transfusion outcomes and improve patient care

Challenges for Thalassemia Patients

1. Frequent transfusions and alloimmunisation

Patients with thalassemia require regular blood transfusions, typically every two to four weeks, to maintain adequate haemoglobin levels. However, repeated exposure to donor RBCs increases the risk of alloimmunisation. Alloimmunisation occurs when the immune system recognises donor RBC antigens as foreign, leading to the production of antibodies against them. This can result in haemolytic transfusion reactions, complicating future transfusions by making it difficult to find compatible donor units. ² Studies suggest that extended phenotypematched transfusions can help mitigate this risk by matching more RBC antigens between donors and recipients. ³ However, implementing extended antigen matching requires extensive donor phenotyping and increased resources, which may not always be feasible, especially in resource-limited settings. The development of multiple alloantibodies further complicates transfusion therapy and can necessitate specialised immunohaematology techniques to identify compatible blood. ⁴

2. Iron overload and its consequences

Chronic RBC transfusions lead to excessive iron accumulation in the body, a condition known as transfusional iron overload. Since the human body lacks a natural mechanism to excrete excess iron, it gradually accumulates in vital organs such as the heart, liver, and endocrine glands, leading to severe complications, including: ⁵

Cardiomyopathy and heart failure:
Iron deposition in the myocardium can cause arrhythmias and cardiomyopathy, which are major causes of mortality in thalassemia patients
Liver cirrhosis and fibrosis:
Chronic iron overload can lead to hepatic dysfunction, cirrhosis, and an increased risk of hepatocellular carcinoma
Endocrine dysfunction:
Iron accumulation in endocrine glands can lead to diabetes, hypogonadism, growth retardation, and thyroid dysfunction.

3. Risk of transfusion-transmitted infections (TTIs)

Despite stringent donor screening and improved testing technologies, the risk of transfusion-transmitted infections remains a concern for thalassemia patients who require frequent transfusions. Infectious agents such as hepatitis B, hepatitis C, and human immunodeficiency virus (HIV) can still pose a threat, especially in regions with high disease prevalence or limited screening infrastructure. ⁴ Emerging infectious diseases present additional challenges, as new pathogens may not be detected by conventional screening methods. Viruses such as Zika virus and dengue virus have raised concerns regarding transfusion safety in endemic regions. Continuous advancements in blood screening technologies and improved donor selection criteria are necessary to mitigate these risks. ⁶

4. Development of autoantibodies

Some thalassemia patients develop autoantibodies against their own RBCs, a condition known as autoimmune haemolytic anaemia (AIHA). This makes transfusion management even more challenging, as cross-matching becomes increasingly difficult. Patients with both alloantibodies and autoantibodies may experience severe haemolytic reactions, necessitating corticosteroid treatment or immunosuppressive therapy in severe cases. Finding compatible donor units for such patients requires advanced immunohaematology techniques, specialised expertise, and often, access to international rare donor registries. ²

Role of Blood Bankers in Transfusion Management

Blood bankers play a critical role in optimising transfusion therapy for thalassemia patients. Their responsibilities extend beyond simple blood typing and include: ³

Conducting regular antibody screening to detect alloimmunisation at an early stage

Utilising advanced serological and molecular typing techniques to improve donor-recipient matching

Maintaining registries of rare phenotype donors to facilitate the provision of compatible blood

Implementing quality assurance measures to minimise transfusion-related risks

Challenges for Blood Bankers

1. Finding antigen-matched blood

Providing antigen-matched blood is essential to minimise alloimmunisation and transfusion complications. However, the availability of such units remains limited, particularly in regions where comprehensive donor phenotyping is not routinely performed.1 This challenge is particularly pronounced for multi-transfused patients who have developed multiple antibodies, necessitating extensive donor screening and molecular genotyping to identify compatible units. ⁴

2. Managing limited rare blood stocks

Maintaining an adequate inventory of rare blood types is a constant challenge for blood banks. Patients who require Rh- and Kell-matched blood place additional pressure on blood banks to recruit and retain donors with specific phenotypes. Strategies to address this challenge include implementing donor phenotyping programmes, establishing rare donor registries, and encouraging repeat donations from antigen-matched donors.⁶

3. Advanced testing and phenotyping

Serological and molecular techniques, such as polymerase chain reaction (PCR)-based genotyping, enable precise antigen matching and reduce the likelihood of alloimmunisation. However, these methods are costly and not widely available in all blood centres. Investment in advanced blood typing technologies and automation is essential to enhance transfusion safety and efficiency. ³

4. Emergency situations

In emergency scenarios requiring immediate transfusion, identifying compatible blood can be time-consuming. In the absence of pre-transfusion extended antigen typing, there is an increased risk of transfusing incompatible units, leading to adverse reactions. Blood banks must implement rapid crossmatching techniques and emergency transfusion protocols to ensure timely and safe transfusions for thalassemia patients. ⁴

The Way Forward

To overcome these challenges, several strategies can be implemented:

Establishing rare blood donor registries:
Blood banks should collaborate with national and international donor registries to maintain a readily available stock of antigen-negative blood. ¹

Routine extended antigen typing:
Implementing molecular and serological typing for both patients and donors can help in finding compatible matches and reducing the risk of alloimmunisation.⁵

Encouraging regular blood donations:
Awareness campaigns, donor incentives, and public education can help increase the pool of voluntary blood donors, ensuring a steady supply of compatible units.⁴

Investment in advanced immunohaematology techniques:
Blood banks should adopt automation, molecular genotyping, and solid phase red cell adherence (SPRCA) methods for accurate and rapid antibody detection.⁴

Early alloimmunisation prevention strategies:
Providing extended antigen-matched blood from the first transfusion can help prevent alloantibody formation, significantly improving long-term transfusion outcomes in thalassemia patients.⁴

Conclusion:

Thalassemia remains a major transfusion-dependent disorder requiring meticulous blood management strategies. The challenges faced by patients, including alloimmunisation, iron overload, TTIs and autoantibody formation, demand a proactive approach to transfusion care. Blood bankers, in turn, must manage antigen-matching challenges, limited donor availability and the financial burden of advanced serological and molecular testing. ⁴ A comprehensive transfusion management plan should include routine phenotyping of patients and donors, maintenance rare donor inventories, and promotion of voluntary blood donation programmes. Additionally, integrating molecular diagnostic tools in blood banks can improve transfusion compatibility and reduce complications in chronically transfused patients.⁶ Collaboration among transfusion centres, blood banks, and healthcare professionals is essential to enhance transfusion safety and ensure that thalassemia patients receive the best possible care. Future advancements in immunohaematology, including gene therapy and novel transfusion protocols, may further revolutionise the management of thalassemia, ultimately reducing dependence on blood transfusions⁶ The key to improving transfusion outcomes lies in early intervention, technological advancements, and increasing public awareness about the importance of rare blood donations. By addressing these challenges, transfusion management for thalassemia patients can be significantly improved, ensuring safer and more efficient care.⁶

Sangeeta Pathak. Challenges of Blood Centres in Providing Compatible Packed Red Blood Cells in

Thalassemia Patients. MMJ. 2026, March. Vol 3 (1)

DOI: XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

References

Fung MK, Grossman BJ, Hillyer CD, et al. AABB Technical Manual. 19th Edition. Bethesda: AABB; 2017.
Waldis SJ, Uter S, Kavitsky D, et al. Rh alloimmunization in chronically transfused patients with thalassemia receiving RhD, C, E, and K matched transfusions. Blood Adv. 2021;5(3):737–44.
Fasano RM, Chou ST. Red Blood Cell Antigen Genotyping for Sickle Cell Disease, Thalassemia, and Other Transfusion Complications. Transfus Med Rev. 2016;30(4):197–201.
Vichinsky E, Neumayr L, Trimble S, et al. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). Transfusion. 2014;54(4):972–81.
Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program. 2017;2017(1):265–71.
Cappellini MD, Cohen A, Porter J, et al. Guidelines for the management of transfusion-dependent thalassemia (TDT). 3^rd Edition. Nicosia, Cyprus: Thalassemia International Federation; 2014.